Your browser is no longer supported. Please, upgrade your browser.
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-3.11 Insider Own0.70% Shs Outstand19.92M Perf Week-10.51%
Market Cap432.17M Forward P/E- EPS next Y-4.22 Insider Trans-29.10% Shs Float19.69M Perf Month-10.47%
Income-49.50M PEG- EPS next Q-0.69 Inst Own99.80% Short Float6.81% Perf Quarter-8.70%
Sales- P/S- EPS this Y26.10% Inst Trans1.88% Short Ratio13.80 Perf Half Y-12.75%
Book/sh10.19 P/B2.12 EPS next Y-27.50% ROA-33.10% Target Price- Perf Year-13.24%
Cash/sh10.24 P/C2.11 EPS next 5Y16.00% ROE-34.90% 52W Range18.01 - 42.36 Perf YTD-11.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.94% Beta-
Dividend %- Quick Ratio25.90 Sales past 5Y- Gross Margin- 52W Low20.07% ATR1.79
Employees26 Current Ratio25.90 Sales Q/Q- Oper. Margin- RSI (14)40.26 Volatility10.55% 7.05%
OptionableYes Debt/Eq0.00 EPS Q/Q54.80% Profit Margin- Rel Volume0.73 Prev Close20.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume97.09K Price21.63
Recom1.40 SMA20-14.05% SMA50-11.87% SMA200-17.18% Volume71,141 Change6.19%
Apr-21-21Initiated Cantor Fitzgerald Overweight $58
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
May-12-21 04:05PM  
May-07-21 04:50AM  
May-05-21 08:00AM  
Apr-05-21 08:00AM  
Mar-24-21 04:05PM  
Mar-20-21 11:00AM  
Mar-11-21 08:00AM  
Mar-03-21 08:00AM  
Feb-24-21 08:00AM  
Feb-18-21 08:00AM  
Jan-22-21 08:36AM  
Jan-05-21 08:00AM  
Jan-04-21 08:00AM  
Dec-18-20 01:40AM  
Nov-24-20 08:00AM  
Nov-13-20 08:00AM  
Nov-10-20 04:02PM  
Nov-08-20 09:29AM  
Nov-02-20 08:00AM  
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
07:01AM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
12:09PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grunberg GregoryDirectorApr 21Sale27.6085023,4600Apr 23 05:27 PM
Martins RyanChief Financial OfficerApr 19Option Exercise3.1110,00031,10017,500Apr 20 06:03 PM
Martins RyanChief Financial OfficerApr 19Sale25.0010,000250,0007,500Apr 20 06:03 PM
Waisbourd RamSee RemarksApr 16Option Exercise1.937,00013,5107,000Apr 19 04:45 PM
Waisbourd RamSee RemarksApr 16Sale24.227,000169,5400Apr 19 04:45 PM
Waisbourd RamSee RemarksMar 16Option Exercise1.937,00013,5107,000Mar 17 04:30 PM
Waisbourd RamSee RemarksMar 16Sale24.207,000169,4000Mar 17 04:30 PM
Hayden Michael RDirectorFeb 23Option Exercise2.1380,904172,23680,904Feb 25 05:01 PM
Waisbourd RamSee RemarksFeb 16Option Exercise1.937,00013,5107,000Feb 17 04:22 PM
Waisbourd RamSee RemarksFeb 16Sale23.397,000163,7300Feb 17 04:22 PM
Waisbourd RamSee RemarksJan 19Option Exercise1.937,00013,5107,000Jan 20 04:30 PM
Waisbourd RamSee RemarksJan 19Sale21.167,000148,1200Jan 20 04:30 PM
Waisbourd RamSee RemarksDec 16Option Exercise1.937,00013,5107,000Dec 18 05:00 PM
Waisbourd RamSee RemarksDec 16Sale27.047,000189,2800Dec 18 05:00 PM
Le-Nguyen QuocSee RemarksNov 16Option Exercise3.114,54814,1444,548Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Option Exercise1.937,00013,5107,000Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Sale27.397,000191,7300Nov 18 04:00 PM
Le-Nguyen QuocSee RemarksNov 16Sale28.114,548127,8440Nov 18 04:00 PM
ORBIMED ADVISORS LLCDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:09 PM
Naschitz AnatDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17Buy28.001,300,00036,400,0004,736,214Sep 21 04:30 PM
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM